[
  {
    "ts": null,
    "headline": "China Biotech’s Stunning Advance Is Changing the World’s Drug Pipeline",
    "summary": "(Bloomberg) -- The biotechnology industry is experiencing a tectonic shift, driven by Chinese drugmakers who have come a long way from their copycat days to challenge Western dominance on innovation.Most Read from BloombergWhy Did Cars Get So Hard to See Out Of?How German Cities Are Rethinking Women’s Safety — With TaxisPhiladelphia Reaches Pact With Workers to End Garbage StrikeThe number of novel drugs in China — for cancer, weight-loss and more — entering into development ballooned to over 1,",
    "url": "https://finnhub.io/api/news?id=45122cb2eae121827e1131eeefd8c0cf50691bb7331ba7450885a84b10e009a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752440420,
      "headline": "China Biotech’s Stunning Advance Is Changing the World’s Drug Pipeline",
      "id": 135920183,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- The biotechnology industry is experiencing a tectonic shift, driven by Chinese drugmakers who have come a long way from their copycat days to challenge Western dominance on innovation.Most Read from BloombergWhy Did Cars Get So Hard to See Out Of?How German Cities Are Rethinking Women’s Safety — With TaxisPhiladelphia Reaches Pact With Workers to End Garbage StrikeThe number of novel drugs in China — for cancer, weight-loss and more — entering into development ballooned to over 1,",
      "url": "https://finnhub.io/api/news?id=45122cb2eae121827e1131eeefd8c0cf50691bb7331ba7450885a84b10e009a9"
    }
  },
  {
    "ts": null,
    "headline": "Why Novartis Is Still A 'Buy' After 15% Surge",
    "summary": "Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks. Find out why NVS stock is a buy.",
    "url": "https://finnhub.io/api/news?id=ed6b3e9c41c0c4097ff67891dd2e8c7caf7cf443c0fb78ffe110c1c84137ab35",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752403500,
      "headline": "Why Novartis Is Still A 'Buy' After 15% Surge",
      "id": 135910850,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1644466793/image_1644466793.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks. Find out why NVS stock is a buy.",
      "url": "https://finnhub.io/api/news?id=ed6b3e9c41c0c4097ff67891dd2e8c7caf7cf443c0fb78ffe110c1c84137ab35"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Reports XTANDI Shows Life-Extending Benefits",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the 13 Best Large Cap Stocks to Buy Right Now. On July 10, Pfizer Inc. (NYSE:PFE) shared positive topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study. This study looked at how XTANDI (enzalutamide), in combination with leuprolide and as a monotherapy, works for […]",
    "url": "https://finnhub.io/api/news?id=b70bfbdeef41878994fa3225045125df4260c5b5e36492fe1108847c22d6c1a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752389321,
      "headline": "Pfizer (PFE) Reports XTANDI Shows Life-Extending Benefits",
      "id": 135911810,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the 13 Best Large Cap Stocks to Buy Right Now. On July 10, Pfizer Inc. (NYSE:PFE) shared positive topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study. This study looked at how XTANDI (enzalutamide), in combination with leuprolide and as a monotherapy, works for […]",
      "url": "https://finnhub.io/api/news?id=b70bfbdeef41878994fa3225045125df4260c5b5e36492fe1108847c22d6c1a7"
    }
  },
  {
    "ts": null,
    "headline": "Arvinas: A Potential 'Sum Of The Parts' Story",
    "summary": "Arvinas: A Potential 'Sum Of The Parts' Story",
    "url": "https://finnhub.io/api/news?id=11d6a00540a95a09007520f271f39e83d748f4e47a511cbb2014c7ddf17adb31",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752377073,
      "headline": "Arvinas: A Potential 'Sum Of The Parts' Story",
      "id": 135904782,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=11d6a00540a95a09007520f271f39e83d748f4e47a511cbb2014c7ddf17adb31"
    }
  }
]